Compare LKFT & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKFT | PRGO |
|---|---|---|
| Founded | N/A | 1887 |
| Country | Belgium | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2007 | 2013 |
| Metric | LKFT | PRGO |
|---|---|---|
| Price | $26.87 | $13.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 221.6K | ★ 2.4M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.68 | $9.23 |
| 52 Week High | $30.91 | $22.65 |
| Indicator | LKFT | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 51.41 |
| Support Level | $25.68 | $13.58 |
| Resistance Level | $29.86 | $13.89 |
| Average True Range (ATR) | 0.55 | 0.58 |
| MACD | -0.19 | -0.15 |
| Stochastic Oscillator | 1.49 | 10.17 |
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.